Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > Articles online first > The Journal of Cardiovascular Surgery 2014 Oct 21





A Journal on Cardiac, Vascular and Thoracic Surgery

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632



The Journal of Cardiovascular Surgery 2014 Oct 21

language: English

Primary stenting is nowadays the golden standard treatment for TASC II A & B iliac lesions: the definitive MISAGO 1-year results

Deloose K. 1, Bosiers M. 1, Callaert J. 1, Verbist J. 2, Vermassen F. 3, Scheinert D. 4, Torsello G. 5, Peeters P. 2

1 Department of Vascular Surgery, AZ Sint‐Blasius, Dendermonde, Belgium;
2 Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium;
3 Department of Thoracic and Vascular Surgery, University Hospital Gent, Gent, Belgium;
4 Department of Angiology, Leipzig Heart Center, Leipzig, Germany;
5 Department of Vascular Surgery, St. Franziskus Hospital and University Hospital of Münster, Münster, Germany


AIM: The MISAGO ILIAC study is a prospective, non­‐randomized, multi‐center, bi­‐national, monitored trial, conducted at 3 hospitals in Belgium and 2 hospitals in Germany. This manuscript reports the findings up to 12­‐month follow‐up time for the total cohort. The primary endpoint of the study is primary potency, defined as a target lesion without a hemodynamically significant stenosis on
duplex ultrasound (>50%, peak systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR), within 12 months.
METHODS: Between September 2011 and April 2012, 120 patients with TASC II Class A or TASC II Class B aortoiliac lesions were included. The cumulative lesion length in the overall population was 45.49 mm with a maximum stenosis pre­‐treatment of 83.76%. The demographic data were compatible for the TASC II Class A and TASC II Class B cohort. One patient with a TASC II class C was included as a protocol deviation.
RESULTS: The primary patency rate for the total patient population was 97.4%. The primary patency rates at 12 months for the TASC II Class A and TASC II Class B(C) lesions were respectively 98.3% and 96.6%. No statistical significant difference was shown when comparing these 2 groups (p=0.6407).
CONCLUSION: Our findings confirm that nowadays primary stenting with modern generation stents replaced the more invasive surgery as the golden standard treatment for patients with TASC II Class A and B aortoiliac lesions.

top of page

Publication History

Cite this article as

Corresponding author e-mail